Global Anti-tumor Drug Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
Scope of the Report:
This report studies the Anti-tumor Drug market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Anti-tumor Drug market by product type and applications/end industries.
In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been "explosive" growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future.
China's bio-pharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of bio-pharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th Five-Year Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the bio-pharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall well-to-do society. Mainly manifested in: small-scale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the long-term development of biomedical industry , Deep-seated problems still exist.
The global Anti-tumor Drug market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Anti-tumor Drug.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Johnson & Johnson
Merck & Co
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
Platinum Antineoplastic Agents
Anthracycline antitumor drugs
Endocrine Therapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs